tolvaptan has been researched along with arginine vasopressin in 63 studies
| Studies (tolvaptan) | Trials (tolvaptan) | Recent Studies (post-2010) (tolvaptan) | Studies (arginine vasopressin) | Trials (arginine vasopressin) | Recent Studies (post-2010) (arginine vasopressin) |
|---|---|---|---|---|---|
| 967 | 172 | 786 | 12,278 | 422 | 1,212 |
| Protein | Taxonomy | tolvaptan (IC50) | arginine vasopressin (IC50) |
|---|---|---|---|
| Vasopressin V2 receptor | Homo sapiens (human) | 0.242 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (3.17) | 18.2507 |
| 2000's | 26 (41.27) | 29.6817 |
| 2010's | 31 (49.21) | 24.3611 |
| 2020's | 4 (6.35) | 2.80 |
| Authors | Studies |
|---|---|
| Aoyama, M; Hirano, T; Itoh, S; Kondo, K; Kotosai, K; Mori, T; Nakamura, S; Ogawa, H; Onogawa, T; Tominaga, M; Tsujimae, K; Tsujimoto, G; Yamada, Y; Yamamura, Y; Yamashita, H; Yamashita, T | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kitano, K; Kondo, K; Miyamoto, H; Mori, T; Nakamura, S; Nakaya, K; Ogawa, H; Onogawa, T; Tanaka, M; Tominaga, M; Yamamura, Y; Yamashita, H | 1 |
| Adams, KF; Barbagelata, A; Elkayam, U; Gattis, WA; Gheorghiade, M; O'Connor, CM; Orlandi, C | 1 |
| Czerwiec, F; Gheorghiade, M; Kambayashi, J; Niazi, I; Orlandi, C; Ouyang, J; Zampino, M | 1 |
| Thibonnier, M | 1 |
| Francis, GS; Tang, WH | 1 |
| Sanghi, P; Schwarz, ER; Uretsky, BF | 1 |
| Golestaneh, L; Le Jemtel, TH; Talreja, A | 1 |
| Streefkerk, JO; van Zwieten, PA | 1 |
| Pham, PC; Pham, PM; Pham, PT | 1 |
| Verbalis, JG | 1 |
| Amat, C; Cristià, E; Moretó, M; Naftalin, RJ | 1 |
| Omland, T; Solberg, OG | 1 |
| Ali, F; Ghali, JK; Guglin, M; Vaitkevicius, P | 1 |
| Balk, RA; Patel, GP | 1 |
| Shoji, M; Yasujima, M | 1 |
| Bramer, SL; Bricmont, P; Shoaf, SE; Zimmer, CA | 1 |
| Aizawa, Y; Kodama, M; Ma, M; Palaniyandi, SS; Suzuki, K; Veeraveedu, PT; Watanabe, K; Yamaguchi, K | 1 |
| Kumar, S; Mather, PJ; Rubin, S; Whellan, DJ | 1 |
| Boerrigter, G; Burnett, JC; Costello-Boerrigter, LC | 2 |
| Haskal, R | 1 |
| Głuszek, J; Olszewski, W | 1 |
| Aizawa, Y; Kodama, M; Ma, M; Palaniyandi, SS; Veeraveedu, PT; Watanabe, K; Yamaguchi, K | 1 |
| Torres, VE | 1 |
| Schweiger, TA; Zdanowicz, MM | 1 |
| Farmakis, D; Filippatos, G; Gheorghiade, M; Kremastinos, DT | 1 |
| Goldsmith, SR | 2 |
| Ghali, JK; Tam, SW | 1 |
| Carluccio, AL; Merlin, MA; Zenenberg, RD | 1 |
| Komai, Y; Palaniyandi, SS; Sukumaran, V; Thandavarayan, RA; Veeraveedu, PT; Watanabe, K; Yamaguchi, K | 1 |
| Chiong, JR; Jao, GT | 1 |
| Cantillo, DS; Comín Colet, J; Robledo, GG | 1 |
| Fürstner, C; Gheorghiade, M; Kolkhof, P; Mondritzki, T; Sabbah, HN; Schaefer, S; Schmeck, C; Siedentop, H; Truebel, H | 1 |
| DeVita, MV; Michelis, MF; Vaghasiya, RP | 1 |
| Deitelzweig, SB; McCormick, L | 1 |
| Azuma, J; Hasunuma, T; Kim, SR; Kondo, M; Okada, T; Sato, O | 1 |
| Fukunami, M; Hori, M; Izumi, T; Matsuzaki, M | 1 |
| Fujiki, H; Nakamura, S; Nakayama, S; Onogawa, T; Sakamoto, Y; Yamamura, Y | 1 |
| Caimi, G; Urso, C | 1 |
| Castillo, JJ; Justice, E; Vincent, M | 1 |
| Akahoshi, Y; Fujiki, H; Iwanaga, Y; Miyazaki, S; Morooka, H; Nakano, Y; Takase, T; Tamaki, Y | 1 |
| Ambrosy, AP; Fought, AJ; Gheorghiade, M; Goldsmith, SR; Greene, SJ; Konstam, MA; Kwasny, MJ; Lanfear, DE; Maggioni, AP; Sabbah, HN; Swedberg, K; Yancy, CW; Zannad, F | 1 |
| Hori, M | 1 |
| Burnett, J; Gheorghiade, M; Grinfeld, L; Hauptman, PJ; Konstam, MA; Kostic, D; Krasa, HB; Maggioni, A; Ouyang, J; Swedberg, K; Udelson, JE; Zannad, F; Zimmer, C | 1 |
| Goldsmith, SR; Kalra, A; Maharaj, V | 1 |
| Iwao, H; Izumi, Y; Miura, K | 1 |
| Aoki, A; Asano, T; Ikoma, A; Ishikawa, SE; Kakei, M; Kusaka, I; Yamada, H; Yamashita, T; Yoshida, M | 1 |
| Fujino, T; Hatano, M; Imamura, T; Inaba, T; Kinugawa, K; Komuro, I; Maki, H; Yao, A | 1 |
| Sato, N | 1 |
| Imamura, T; Kinugawa, K | 2 |
| Akaike, M; Bando, M; Bando, S; Hara, T; Ise, T; Iwase, T; Kadota, M; Kawabata, Y; Matsuura, T; Ogasawara, K; Sata, M; Soeki, T; Ueno, R; Wakatsuki, T; Yagi, S; Yamada, H; Yamaguchi, K | 1 |
| Imamura, T; Kinugawa, K; Komuro, I; Nitta, D | 1 |
| Gustafsson, F; Vishram-Nielsen, JK | 1 |
| Ando, F; Kagechika, H; Kondo, Y; Mori, S; Morimoto, T; Nomura, N; Rai, T; Sasaki, S; Sohara, E; Uchida, S; Yui, N | 1 |
| Alvear-Perez, R; Bonnet, D; De Mota, N; Estéoulle, L; Flahault, A; Girault-Sotias, PE; Iturrioz, X; Keck, M; Llorens-Cortes, C; Ramanoudjame, SM | 1 |
| Doi, T; Fukahara, K; Imamura, T; Kinugawa, K; Yamashita, S; Yokoyama, S; Yoshimura, N | 1 |
| Bankir, L; Bichet, DG; Guerrot, D | 1 |
| Fujioka, H; Imamura, T; Kakeshita, K; Kinugawa, K; Koike, T; Yamazaki, H | 1 |
31 review(s) available for tolvaptan and arginine vasopressin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Vasopressin receptor antagonists in heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Pyrroles; Randomized Controlled Trials as Topic; Tolvaptan | 2003 |
Vasopressin antagonism: a future treatment option in heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Heart Failure; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Tolvaptan | 2005 |
Vasopressin antagonists in heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Diuretics; Heart Failure; Humans; Randomized Controlled Trials as Topic; Tolvaptan; Water-Electrolyte Balance | 2004 |
Vasopressin receptor antagonists: pharmacological tools and potential therapeutic agents.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Drug Design; Heart Failure; Hormone Antagonists; Humans; Hypertension; Inappropriate ADH Syndrome; Indoles; Presynaptic Terminals; Pyrrolidines; Receptors, Vasopressin; Renal Artery; Sympathetic Nervous System; Synaptic Transmission; Tolvaptan; Vasoconstriction; Vasoconstrictor Agents | 2006 |
Vasopressin excess and hyponatremia.
Topics: Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Humans; Hyponatremia; Pyrroles; Receptors, Vasopressin; Tolvaptan; Water-Electrolyte Balance | 2006 |
AVP receptor antagonists as aquaretics: review and assessment of clinical data.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Humans; Hyponatremia; Pyrroles; Receptors, Vasopressin; Tolvaptan; Water-Electrolyte Balance | 2006 |
[Arginine vasopressin antagonism--new treatment option in chronic heart failure].
Topics: Animals; Antidiuretic Agents; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Nephrons; Prognosis; Pyrroles; Receptors, Vasopressin; Tolvaptan; Treatment Outcome; Vasoconstrictor Agents | 2007 |
Therapeutic potential of vasopressin receptor antagonists.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Liver Cirrhosis; Morpholines; Pyrroles; Receptors, Vasopressin; Spiro Compounds; Tolvaptan | 2007 |
Recognition and treatment of hyponatremia in acutely ill hospitalized patients.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Critical Illness; Humans; Hyponatremia; Inpatients; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Tolvaptan | 2007 |
[Recent progress in vasopressin research on cardiovascular diseases].
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Biomarkers; Cardiovascular Diseases; Humans; Platelet Aggregation; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Receptors, Vasopressin; Tolvaptan | 2007 |
Hyponatremia and vasopressin antagonism in congestive heart failure.
Topics: Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Chronic Disease; Clinical Trials as Topic; Diuretics; Heart Failure; Humans; Hyponatremia; Models, Biological; Pyrroles; Registries; Renin-Angiotensin System; Sodium; Tolvaptan; Treatment Outcome; Vasopressins | 2007 |
V2 receptor antagonism with tolvaptan in heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Clinical Trials as Topic; Diuretics; Heart Failure; Humans; Tolvaptan | 2007 |
Current issues for nurse practitioners: Hyponatremia.
Topics: Aged; Algorithms; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Causality; Decision Trees; Diagnosis, Differential; Early Diagnosis; Female; Homeostasis; Humans; Hyponatremia; Nurse Practitioners; Nurse's Role; Nursing Assessment; Patient Selection; Primary Health Care; Pyrroles; Tolvaptan; Water-Electrolyte Balance | 2007 |
[Vasopressin antagonists in treatment of hyponatremia].
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Heart Failure; Hormone Antagonists; Humans; Hyponatremia; Inappropriate ADH Syndrome; Liver Cirrhosis; Sodium Chloride; Tolvaptan; Water-Electrolyte Balance | 2007 |
Role of vasopressin antagonists.
Topics: Adolescent; Adult; Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Body Fluids; Cell Proliferation; Drug Evaluation, Preclinical; Hormone Antagonists; Humans; Kidney; Male; Polycystic Kidney, Autosomal Dominant; Receptors, Vasopressin; Tolvaptan; Treatment Outcome | 2008 |
Vasopressin-receptor antagonists in heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Cardiovascular Agents; Chronic Disease; Heart Failure; Humans; Hyponatremia; Pyrroles; Receptors, Vasopressin; Tolvaptan | 2008 |
Vasopressin and vasopressin antagonists in heart failure and hyponatremia.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heart Failure; Humans; Hyponatremia; Infusions, Intravenous; Male; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Risk Assessment; Survival Rate; Tolvaptan; Water-Electrolyte Imbalance | 2008 |
Pharmacology of vasopressin antagonists.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Benzodiazepines; Heart Failure; Humans; Morpholines; Pyrroles; Receptors, Vasopressin; Spiro Compounds; Tolvaptan | 2009 |
Treatment options for hyponatremia in heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Pyrroles; Sodium Potassium Chloride Symporter Inhibitors; Tolvaptan; Treatment Outcome | 2009 |
The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzamides; Benzazepines; Blood Pressure; Blood Volume; Female; Heart Failure; Humans; Hypertension; Hyponatremia; Male; Prevalence; Prognosis; Pyrroles; Receptors, Vasopressin; Tolvaptan; United States; Water-Electrolyte Balance | 2010 |
Hyponatremia: evaluation and management.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Blood Urea Nitrogen; Cardiac Output, Low; Causality; Diagnosis, Differential; Glomerular Filtration Rate; Humans; Hyponatremia; Inappropriate ADH Syndrome; Kidney Tubules; Saline Solution, Hypertonic; Sodium; Tolvaptan; Uric Acid; Water-Electrolyte Balance | 2010 |
Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Clinical Trials as Topic; Drug Evaluation, Preclinical; Heart Failure; Humans; Hyponatremia; Receptors, Vasopressin; Sodium Potassium Chloride Symporter Inhibitors; Tolvaptan | 2010 |
Hyponatremia in acute decompensated heart failure: mechanisms, prognosis, and treatment options.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Biomarkers; Fluid Therapy; Heart Failure; Hormone Antagonists; Humans; Hyponatremia; Receptors, Vasopressin; Renin-Angiotensin System; Sodium; Tolvaptan; Treatment Outcome; Ventricular Dysfunction | 2010 |
[Hyponatremia in heart failure: physiopathology and pharmacological approach].
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzamides; Benzazepines; Body Water; Brain Edema; Demyelinating Diseases; Diuresis; Diuretics; Double-Blind Method; Heart Failure; Humans; Hyponatremia; Kidney; Multicenter Studies as Topic; Natriuresis; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Renin-Angiotensin System; Saline Solution, Hypertonic; Sympathetic Nervous System; Tolvaptan | 2010 |
Hyponatremia in hospitalized patients: the potential role of tolvaptan.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Diagnosis, Differential; Hospitalization; Humans; Hyponatremia; Hypovolemia; Quality Indicators, Health Care; Severity of Illness Index; Time Factors; Tolvaptan | 2011 |
[Hyponatremic syndrome].
Topics: Aging; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Brain; Brain Edema; Exercise; Humans; Hyponatremia; Inappropriate ADH Syndrome; Infections; Inflammation; Kidney; Natriuresis; Neoplasms; Osmotic Pressure; Renal Replacement Therapy; Sodium; Tolvaptan; Water Intoxication | 2012 |
Diagnosis and management of hyponatremia in cancer patients.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Disease Management; Humans; Hyponatremia; Hypovolemia; Inappropriate ADH Syndrome; Neoplasms; Receptors, Vasopressin; Risk Factors; Sodium; Tolvaptan | 2012 |
Vasopressin receptor antagonists: from pivotal trials to current practice.
Topics: Antidiuretic Agents; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Heart Failure; Hormone Antagonists; Humans; Tolvaptan | 2014 |
Therapeutic potential of vasopressin-receptor antagonists in heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzamides; Benzazepines; Body Water; Clinical Trials as Topic; Disease Models, Animal; Heart Failure; Homeostasis; Humans; Hyponatremia; Morpholines; Pyrroles; Receptors, Vasopressin; Spiro Compounds; Tolvaptan; Ventricular Remodeling | 2014 |
Vasopressin and Vasopressin Antagonists in Heart Failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Glycopeptides; Heart Failure; Hemodynamics; Humans; Hyponatremia; Receptors, Vasopressin; Tolvaptan; Vasopressins | 2017 |
8 trial(s) available for tolvaptan and arginine vasopressin
| Article | Year |
|---|---|
Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Disease Progression; Double-Blind Method; Heart Failure; Hospitalization; Humans; Patient Selection; Prospective Studies; Receptors, Vasopressin; Research Design; Tolvaptan | 2003 |
Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Body Weight; Chronic Disease; Diuretics; Double-Blind Method; Edema, Cardiac; Female; Furosemide; Heart Failure; Humans; Hyponatremia; Male; Middle Aged; Osmolar Concentration; Sodium; Tolvaptan; Treatment Outcome; Urinalysis; Water-Electrolyte Balance | 2003 |
Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide.
Topics: Adolescent; Adult; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Cross-Over Studies; Diuretics; Drug Interactions; Furosemide; Humans; Hydrochlorothiazide; Male; Osmolar Concentration; Renin; Sodium; Tolvaptan | 2007 |
Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V2-receptor antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers.
Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Area Under Curve; Arginine Vasopressin; Asian People; Benzazepines; Cross-Over Studies; Diuretics; Dose-Response Relationship, Drug; Double-Blind Method; Food-Drug Interactions; Humans; Male; Potassium; Sodium; Tolvaptan; Young Adult | 2011 |
Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study).
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Body Weight; Diuretics; Double-Blind Method; Edema, Cardiac; Female; Heart Failure; Humans; Male; Middle Aged; Potassium; Sodium; Tolvaptan | 2011 |
Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Cause of Death; Female; Follow-Up Studies; Heart Failure; Humans; Inpatients; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Stroke Volume; Survival Rate; Tolvaptan; United States | 2013 |
Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan.
Topics: Aged; Analysis of Variance; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Diuretics; Dyspnea; Female; Furosemide; Heart Failure, Systolic; Humans; Hyponatremia; Male; Middle Aged; Proportional Hazards Models; Tolvaptan; Weight Loss | 2013 |
Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure.
Topics: Adult; Aged; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Arginine Vasopressin; Benzazepines; Biomarkers; Disease-Free Survival; Female; Heart Failure; Humans; Male; Middle Aged; Survival Rate; Tolvaptan | 2014 |
24 other study(ies) available for tolvaptan and arginine vasopressin
| Article | Year |
|---|---|
OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Blood Urea Nitrogen; Creatinine; Diuretics; Dose-Response Relationship, Drug; HeLa Cells; Humans; Male; Osmolar Concentration; Rats; Rats, Sprague-Dawley; Receptors, Vasopressin; Sodium; Tolvaptan; Transfection | 1998 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl ]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Diuretics; Magnetic Resonance Spectroscopy; Male; Molecular Structure; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Vasopressin; Tolvaptan | 1999 |
Vasopressin receptor antagonists: will the "vaptans" fulfill their promise?
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Cardiovascular Agents; Heart Failure; Humans; Tolvaptan | 2004 |
Role of vasopressin in rat distal colon function.
Topics: Actins; Aldosterone; Animals; Antidiuretic Agents; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Arginine Vasopressin; Benzazepines; Captopril; Colon; Dextrans; Diet, Sodium-Restricted; Drinking; Epithelial Sodium Channels; Fibroblasts; Fluorescein-5-isothiocyanate; Hormone Antagonists; Intestinal Mucosa; Male; Microscopy, Confocal; Osmolar Concentration; Potassium; Rats; Rats, Sprague-Dawley; Sodium; Tolvaptan | 2007 |
Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure.
Topics: Aldosterone; Animals; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Arginine Vasopressin; Benzazepines; Cardiac Myosins; Diuretics; Heart; Heart Failure; Hemodynamics; Kidney; Male; Organ Size; Osmolar Concentration; Rats; Rats, Inbred Lew; Sodium; Tolvaptan | 2007 |
Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
Topics: Aldosterone; Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Blood Pressure; Body Weight; Creatinine; Diuretics; Echocardiography; Furosemide; Heart Failure; Heart Rate; Male; Organ Size; Osmolar Concentration; Potassium; Rats; Rats, Inbred Lew; Renin; Sodium; Tolvaptan; Ventricular Remodeling | 2008 |
Differentiation of arginine vasopressin antagonistic effects by selective V2 versus dual V2/V1a receptor blockade in a preclinical heart failure model.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Blood Pressure; Cardiac Output; Cardiac Pacing, Artificial; Dogs; Heart Failure; Hemodynamics; Pacemaker, Artificial; Tolvaptan; Urodynamics; Vascular Resistance | 2011 |
Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Blood Pressure; Diuretics; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Osmolar Concentration; Sodium; Tolvaptan | 2012 |
Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Atrial Natriuretic Factor; Benzazepines; Blood Pressure; Body Weight; Chlorides; Disease Models, Animal; Diuretics; Dogs; Furosemide; Heart Failure; Kidney; Male; Potassium; Renin; Sodium; Tolvaptan | 2011 |
Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure.
Topics: Administration, Oral; Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Biomarkers; Blood Pressure; Disease Models, Animal; Disease Progression; Drug Administration Schedule; Heart Failure; Hormone Antagonists; Hypertension; Kidney; Kidney Diseases; Male; Myocardium; Natriuretic Peptides; Rats; Rats, Inbred Dahl; Receptors, Vasopressin; RNA, Messenger; Sodium Chloride, Dietary; Time Factors; Tolvaptan; Ultrasonography; Urination; Ventricular Dysfunction, Left; Ventricular Function, Left | 2012 |
Hyponatremia and outcomes in patients with heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Disease Progression; Global Health; Heart Failure; Humans; Hyponatremia; Incidence; Prognosis; Sodium; Survival Rate; Tolvaptan | 2012 |
Tolvaptan for the treatment of hyponatremia and hypervolemia in patients with congestive heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Blood Volume; Dose-Response Relationship, Drug; Heart Failure; Homeostasis; Humans; Hyponatremia; Kidney; Sodium; Tolvaptan; Treatment Outcome | 2013 |
Prompt efficacy of tolvaptan in treating hyponatremia of syndrome of inappropriate secretion of antidiuretic hormone (SIADH) closely associated with rupture of a gastric artery aneurysm.
Topics: Abdominal Pain; Aged; Aneurysm; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Brain; Humans; Hyponatremia; Inappropriate ADH Syndrome; Magnetic Resonance Imaging; Male; Osmolar Concentration; Stomach; Tolvaptan | 2014 |
Awareness of the vasopressin system in heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Arginine Vasopressin; Benzazepines; Female; Heart Failure; Humans; Male; Tolvaptan | 2014 |
Mid-Term Administration of Tolvaptan Improves Renal Function Accompanied by Dose-Reduction in Furosemide in Aquaporin-Defined Responders.
Topics: Antidiuretic Hormone Receptor Antagonists; Aquaporins; Arginine Vasopressin; Benzazepines; Diuretics; Furosemide; Heart Failure; Humans; Kidney Function Tests; Medication Therapy Management; Patient Selection; Tolvaptan | 2015 |
Response Prediction and Influence of Tolvaptan in Chronic Heart Failure Patients Considering the Interaction of the Renin-Angiotensin-Aldosterone System and Arginine Vasopressin.
Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Body Mass Index; Female; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Renin-Angiotensin System; Tolvaptan; Treatment Outcome | 2016 |
Tolvaptan Improves the Long-Term Prognosis in Patients With Congestive Heart Failure With Preserved Ejection Fraction as Well as in Those With Reduced Ejection Fraction.
Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Arginine Vasopressin; Benzazepines; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Stroke Volume; Tolvaptan | 2016 |
Tolvaptan Reduces Long-Term Total Medical Expenses and Length of Stay in Aquaporin-Defined Responders.
Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Arginine Vasopressin; Benzazepines; Female; Health Care Costs; Heart Failure; Humans; Length of Stay; Male; Middle Aged; Prognosis; Retrospective Studies; Stroke Volume; Tolvaptan | 2016 |
AKAPs-PKA disruptors increase AQP2 activity independently of vasopressin in a model of nephrogenic diabetes insipidus.
Topics: A Kinase Anchor Proteins; Amino Acid Sequence; Animals; Aquaporin 2; Arginine Vasopressin; Benzazepines; Benzhydryl Compounds; Cell Line, Transformed; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Diabetes Insipidus, Nephrogenic; Disease Models, Animal; Epithelial Cells; Gene Expression Regulation; Humans; Kidney Tubules, Collecting; Male; Mice, Inbred C57BL; Osmolar Concentration; Phenols; Protein Binding; Receptors, Vasopressin; Tolvaptan; Water | 2018 |
A metabolically stable apelin-17 analog decreases AVP-induced antidiuresis and improves hyponatremia.
Topics: Amino Acid Sequence; Animals; Apelin; Apelin Receptors; Arginine Vasopressin; Blood Glucose; Blood Pressure; Cell Line; Colforsin; Cyclic AMP; Deamino Arginine Vasopressin; Disease Models, Animal; Diuresis; Electrolytes; Half-Life; Hyponatremia; Kidney Tubules, Collecting; Male; Mice; Models, Biological; Myocardial Contraction; Peptides; Phosphorylation; Rats, Sprague-Dawley; Tolvaptan | 2021 |
Peak Lag Between Plasma Vasopressin and Urine Aquaporin-2 Following Cardiac Surgery.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Arginine Vasopressin; Biomarkers; Body Fluids; Cardiac Surgical Procedures; Female; Heart Failure; Hemodynamics; Humans; Kidney; Male; Middle Aged; Postoperative Care; Prospective Studies; Tolvaptan; Vasopressins | 2021 |
Vaptans or voluntary increased hydration to protect the kidney: how do they compare?
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Dinoprostone; Humans; Kidney; Kidney Medulla; Receptors, Vasopressin; Sodium; Tolvaptan | 2023 |
Impact of urine cyclic AMP relative to plasma arginine vasopressin on response to tolvaptan in patients with chronic kidney disease and heart failure.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Cyclic AMP; Heart Failure; Humans; Male; Prospective Studies; Renal Insufficiency, Chronic; Tolvaptan | 2023 |